Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer - Drescher, C.; Moore, K.N.; Liu, J.F.; O’Malley, D.M.; Wang, E.W.; Wang, J.S.-Z.; Subbiah, V.; Wilky, B.A.; Yuan, G.; Dupont, C.D.; Gonzalez, A.M.; Savitsky, D.; et al. (Annals of oncology, 2018)